BioSpace News Archive

PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will present an e-poster featuring non-clinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.

MannKind Corporation announced that on April 22, 2021 it and MidCap Financial Trust, as agent, entered into an amendment of the credit and security agreement dated August 6, 2019.

CORAT Therapeutics GmbH announced the start of a clinical trial with COR-101 for treatment of COVID-19 in hospitalized patients. The novel therapeutic antibody may complement currently approved antibody drugs, which are not indicated for moderate to severe COVID-19 cases due to side effects during advanced stages of the disease.

The Muscular Dystrophy Association announced programming and fundraising events in support of people living with Amyotrophic Lateral Sclerosis throughout ALS Awareness Month in May, and participation in Major League Baseball’s designation of Lou Gehrig’s Day on June 2, in the effort to cure the disease.

Bugworks Research, Inc (“Bugworks”), secures funding from the Defense Threat Reduction Agency (DTRA) to support development of its novel broad-spectrum antibiotic BWC0977, against the most critical bacterial biothreats.

Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted cellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, today announced the appointment of William Sandborn, M.D. as Chief Medical Officer.

Cynosure announced today the U.S. launch of its one-of-a-kind Fusion Tip, the newest addition to its best-in-class Potenza™ radiofrequency (RF) microneedling system.

Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today new data demonstrating an unexpected synergy between its inducible pluripotent stem cell (StemVacs-V iPSC) derived immunotherapy product with low dose cyclophosphamide in evoking potent immune mediated cancer regression.

Modern Vascular, a pioneering medical group dedicated to preventing amputation through the treatment of Peripheral Artery Disease (PAD), today announced the expansion of its national footprint to 14 clinics with the opening of a new office in Indianapolis.

Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the publication of its successful Phase 2b knee osteoarthritis clinical trial data in Osteoarthritis and Cartilage.